Oryzon Genomics S.A./€ORY
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Oryzon Genomics S.A.
Oryzon Genomics S.A. is a Spanish biotechnology company focused on developing innovative therapies through the discovery and development of epigenetic therapeutics. Founded in 2000 and headquartered in Madrid, Spain, Oryzon's research concentrates on LSD1 inhibitors, primarily for oncology and neurodegenerative diseases. The company's leading compounds include iadademstat for cancer treatment and vafidemstat for neurological conditions. Oryzon's unique position in the epigenetics field is supported by its extensive intellectual property portfolio and strategic partnerships with leading pharmaceutical entities. The company operates within the broader pharmaceutical and biotechnology industry, with a specific focus on drug discovery and development.
Ticker
€ORY
Sector
Primary listing
BME
Employees
46
Headquarters
Website
ORY Metrics
BasicAdvanced
€245m
-
-€0.03
0.43
-
Price and volume
Market cap
€245m
Beta
0.43
52-week high
€3.88
52-week low
€2.59
Average daily volume
107k
Financial strength
Profitability
EBITDA (TTM)
-8.128
Gross margin (TTM)
97.42%
Net profit margin (TTM)
-20.43%
Operating margin (TTM)
-75.34%
Effective tax rate (TTM)
57.26%
Revenue per employee (TTM)
€234,330
Management effectiveness
Valuation
Price to revenue (TTM)
22.159
Growth
Revenue change (TTM)
58.51%
Earnings per share change (TTM)
-52.80%
3-year revenue growth (CAGR)
-9.58%
10-year revenue growth (CAGR)
4.32%
3-year earnings per share growth (CAGR)
-26.69%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs